| 06/11/19 |
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
|
|
| 05/07/19 |
Denali Therapeutics Reports First Quarter 2019 Financial Results
|
|
| 03/12/19 |
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
|
|
| 02/15/19 |
Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease
|
|
| 01/08/19 |
Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS
|
|
| 12/10/18 |
Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson's Disease
|
|
| 11/19/18 |
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
|
|
| 11/08/18 |
Denali Therapeutics Reports Third Quarter 2018 Financial Results And Business Highlights And Announces The Appointment Of Jennifer Cook To Board Of Directors
|
|
| 10/31/18 |
Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases
|
|
| 10/03/18 |
CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials
|
|